Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.34), $0.17 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $22.65 million versus the consensus estimate of $10.89 million.

"Our 2016 accomplishments, including the enasidenib NDA submission with our collaboration partner Celgene and clear proof-of-concept data for our PK deficiency program, demonstrate our ability to transform our scientific discoveries into important precision medicines,” said David Schenkein, M.D., chief executive officer at Agios. “In 2017, we are focused on making the transition to a commercial stage company by delivering our lead cancer programs to patients, bringing our first rare genetic disease program into pivotal development and advancing our next research program, focused on MTAP-deleted cancers, into the clinic

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.